For generations, autism has been spoken of as a single condition demanding a single kind of response — yet the brain has always told a more intricate story. A team of neuroscientists has now traced two separate neural pathways in the anterior cingulate cortex of mice, each governing a distinct behavioral symptom associated with autism: one shaping sociability, another regulating attention. The discovery invites a quieter but profound reorientation — away from treating a diagnosis and toward treating a person, circuit by circuit.
Distinct Brain Circuits Control Social and Attentional Behaviors in Autism Model
Cobertura Relacionada
Anthony Mancinelli, certified as the world's oldest working barber at 96, continued cutting hair full-time until age 107…
chemeurope.com · Sep 04 Scientists Discover 'Pac-Man Enzyme' That Degrades Plastic and AntibioticsUniversity of Konstanz researchers discovered a "Pac-Man enzyme" in bacteria that breaks down polyester plastics and bio…
timesofindia.indiatimes.com · Sep 04 ISRO's GSLV-F17 Successfully Deploys EOS-05 to Geosynchronous OrbitISRO's GSLV-F17 rocket successfully placed India's first geosynchronous imaging satellite EOS-05 into orbit from Srihari…
News-Medical · Sep 04 UFC Fighters Dramatically Shift Diet Across Weigh-In Cycle, Study FindsA study of 107 professional MMA fighters reveals highly structured eating patterns, with severe carbohydrate and fluid r…
Viés e Enquadramento
Scientific reporting on autism neurobiology research with neutral, evidence-based framing and appropriate caveats about translational potential.
Standard science journalism presenting research findings with appropriate hedging language ('may inform,' 'potential targets'). Uses mouse model research to discuss autism mechanisms without overstating clinical implications.
Impacto Geopolítico
This is neuroscience research, not geopolitical news. No international implications or power dynamics apply.
Lente Econômica
Neuroscience research identifying distinct brain circuits for autism symptoms offers potential for targeted therapeutics, creating opportunities in psychiatric drug development and precision medicine sectors.
Patients with autism and related psychiatric conditions may eventually benefit from more targeted, symptom-specific treatments with potentially fewer side effects. This could reduce overall healthcare costs through improved treatment efficacy and reduced trial-and-error medication approaches.
Findings may accelerate FDA approval pathways for precision psychiatric medicines. Could influence mental health parity regulations and insurance coverage policies for autism-related treatments. May prompt increased research funding allocation to neurodevelopmental disorder research and circuit-based therapeutic approaches.